抗柯萨奇 B病毒性心肌炎胶囊复方新制剂对柯萨奇 B3病毒感染的人喉癌上皮细胞的影响

目的：观察不同浓度抗柯萨奇B病毒性心肌炎胶囊（ K-CoxB-JN）复方新制剂对柯萨奇B3病毒（CVB3）感染人喉癌上皮（Hep-2）细胞的影响。方法首先测定K-CoxB-JN复方新制剂的最大无毒浓度（TC0），再通过K-CoxB-JN复方新制剂不同的加药和加病毒方式，用溴化噻唑蓝四氮唑（MTT）法检测对CVB3感染Hep-2细胞的活性，观察K-CoxB-JN复方新制剂对CVB3感染Hep-2细胞的影响，并采用利巴韦林颗粒对照观察。结果测得K-CoxB-JN复方新制剂TC0为1．5625 mg/mL，利巴韦林颗粒TC0为6．25 mg/mL；当K-CoxB-JN复方新制剂浓度为0．78125 mg/mL、利巴韦林浓度为3．125 mg/mL时对CVB3感染Hep-2细胞保护作用最明显；当K-CoxB-JN复方新制剂浓度为1．5625 mg/mL、利巴韦林颗粒浓度为6．25 mg/mL时直接抗病毒和抑制病毒释放作用最明显，并且表现出良好的量效关系。结论不同浓度的K-CoxB-JN复方新制剂对CVB3感染的Hep-2细胞具有保护作用，能直接抗CVB3病毒，并且能抑制病毒的释放。

Effect of new compound preparation of anti-Coxsackie B viral myocarditis capsules on Coxsackie virus B3 with infection of human laryngeal epithelial cells

Objective To explore the effect of different concentration new compound preparation of anti -Coxsackie B viral myocarditis capsules on Coxsackie virus B 3 （ CVB3 ） with infection of human laryngeal epithelial （Hep-2） cells.Methods Maximum non -toxic concentrations of anti -Coxsackie B viral myocarditis capsules was detected .Activity of anti-Coxsackie B viral myocarditis capsules for CVB 3 with infection of Hep -2 cells was measured using MTT Methods through different way of dosing and processing virus .The effect of different concen-tration new compound preparation of anti -Coxsackie B viral myocarditis capsules on CVB 3 with infection of Hep-2 cells was observed and the use of ribavirin particles was observed as control at same time .Results Maximum non-toxic concentrations of anti -Coxsackie B viral myocarditis capsules was 1.562 5 mg/mL.Maximum non-toxic con-centrations of ribavirin particles was 6.25 mg/mL.Protection of 0.781 25 mg/mL anti-Coxsackie B viral myocarditis capsules was more obvious on CVB 3 with infection of Hep-2 cells,protection of 3.125 mg/mL ribavirin particles was more obvious on the protection of CVB 3 with infection of Hep-2 cells.1.562 5 mg/mL anti-Coxsackie B viral myo-carditis capsules 6.25 mg/mL ribavirin particles show the most obvious direct antiviral effect and inhibition of virus release.Conclusion Different concentration new compound preparation of anti -Coxsackie B viral myocarditis cap-sules has protection on CVB 3 with infection of Hep -2 cells, can directly resist Coxsackie B 3 virus and inhibit release of the virus .